Judith S. Hochman, MD

Judith S. Hochman, MD

Medicine (Cardiology), Program Co-Director, Primary Mentor

Judith S. Hochman, M.D., is the Senior Associate Dean for Clinical Sciences, Co-Director of the NYU-HHC Clinical and Translational Science Institute, Harold Snyder Family Professor and Associate Director of the Leon Charney Division of Cardiology and Director of the Cardiovascular Clinical Research Center at NYU Langone Medical Center.

Dr. Hochman holds a Masters Degree in Cellular and Developmental Biology from Harvard University and an M.D. from Harvard Medical School. She completed Internal Medicine training at the Peter Bent Brigham Hospital and Fellowship in Cardiovascular Medicine at the Johns Hopkins University Medical Center. She currently serves on the National Heart Lung and Blood Institute (NHLBI) Board of External Experts and the Science Advisory Coordinating Committee of the American Heart Association, on the FDA/CDER Cardiovascular and Renal Drugs Advisory Committee, the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Practice Guidelines, and the AHA National Research Committee. She has authored over 250 publications and chapters in major internal medicine and cardiovascular textbooks. She is a Senior Guest Editor for Circulation and serves on editorial boards of European Heart Journal and American Heart Journal.

She has led, as Study Chair, NHLBI funded international randomized clinical trials that tested the optimal management for subsets of patients with ischemic heart disease. These studies led to two new recommendations regarding the role of revascularization (stents and coronary bypass surgery) in the ACC/AHA Practice Guidelines. Dr. Hochman is currently leading an NHLBI funded comparative effectiveness ISCHEMIA trial in over 300 sites in 33 countries worldwide comparing a routine invasive strategy (cardiac catheterization with stents or coronary bypass surgery) and an initial conservative strategy in patients with stable ischemic heart disease and at least moderate ischemia.  She was also the Study Chair for the first phase 2 and phase 3 multicenter randomized trials conducted to test a pharmacologic agent, a nitric oxide synthase inhibitor, for cardiogenic shock (SHOCK 2 and TRIUMPH). She has also served on numerous Data Safety Monitoring Boards and Steering Committees of international clinical trials investigating the role of novel agents in acute coronary syndromes and stable ischemic heart disease. 

Dr. Hochman has also served as a mentor for numerous trainees who have gone on to have successful independent careers. In 2008 she received the American Heart Association Women in Cardiology Mentoring Award. She is a 2014 Awardee of the AHA Clinical Research Prize.